Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 5, 2013, Pages 1080-1087

  Dincer, Sebla ^a   Cetin, Kadir Taylan ^a   Onay Besikci, Arzu ^a   Ölgen, Süreyya ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Docking analysis; Inhibition of SFK; Pyrrolopyrimidine derivatives; Selectivity; Synthesis

Indexed keywords

2 AMINO 5 [AMINOMETHYL]PYRROLO[2,3 D]PYRIMIDIN 4[3 H] ONE; 5 [CYANO] 2 AMINOPYRROLO[2,3 D]PYRIMIDIN 4[3H] ONE; AMIDE; HEMATOPOIETIC CELL KINASE; N [[2 AMINO 4 OXO 4,7 DIHYDRO 3H PYRROLO(2,3-D)PYRIMIDIN 5 YL]METHYL] 2 [CHLOROPHENOXY]ACETAMIDE; N [[2 AMINO 4 OXO 4,7 DIHYDRO 3H PYRROLO(2,3-D)PYRIMIDIN 5 YL]METHYL] 4 [3,4 DIMETHOXY PHENYL]; N [[2 AMINO 4 OXO 4,7 DIHYDRO 3H PYRROLO(2,3-D)PYRIMIDIN 5 YL]METHYL] 4 [METHYLTHIO] BENZAMIDE; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN KINASE P60; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; MOLECULAR DOCKING; PRIORITY JOURNAL;

CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884275896     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.715288     Document Type: Article

References (34)

1. Ingley E. Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 2008;1784:56-65.
2. Parang K, Sun G. Recent advances in the discovery of Src kinase inhibitors. Expert Opin Ther Patents 2005;15:1183-1207.
3. Gupta S, El-Rayes BF. Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics 2008;2:707-715.
4. Chong YP, Ia KK, Mulhern TD, Cheng HC. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochim Biophys Acta 2005;1754:210-220.
5. Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct 2011;2011:865819.
6. Cao X, You QD, Li ZY, Wang XJ, Lu XY, Liu XR et al. Recent progress of SRC family kinase inhibitors as anticancer agents. Mini Rev Med Chem 2008;8:1053-1063.
7. Roskoksi R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophysical Res Commun 2005;331:1-14.
8. Hu G, Place AT, Minshall RD. Regulation of endothelial permeability by Src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules. Chem Biol Interact 2008;171:177-189.
9. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379-1386.
10. Edwards J. Src kinase inhibitors: An emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs 2010;19:605-614.
11. Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: Current status and future directions. Clin Lung Cancer 2010;11:238-242.
12. Sakamoto M, Takamura M, Ino Y, Miura A, Genda T, Hirohashi S. Involvement of c-Src in carcinoma cell motility and metastasis. Jpn J Cancer Res 2001;92:941-946.
13. Sawyer TK. Cancer metastasis therapeutic targets and drug discovery: Emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 2004;13:1-19.
14. Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem 2008;8:342-349.
15. Saad F, Lipton A. SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177-184.
16. Martin MW, Machacek MR. Update on lymphocyte specific kinase inhibitors: A patent survey. Expert Opin Ther Pat 2010;20:1573-1593.
17. Smolinska MJ, Page TH, Urbaniak AM, Mutch BE, Horwood NJ. Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. J Immunol 2011;187:6043-6051.
18. Poincloux R, Al Saati T, Maridonneau-Parini I, Le Cabec V. The oncogenic activity of the Src family kinase Hck requires the cooperative action of the plasma membrane- and lysosomeassociated isoforms. Eur J Cancer 2009;45:321-327.
19. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: Role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011;118:1885-1898.
20. Resh MD. Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol 1998;30:1159-1162.
21. Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: A novel molecular target in cancer. Cancer 2010;116:1629-1637.
22. Belsches-Jablonski AP, Demory ML, Parsons JT, Parsons SJ. The src pathway as a therapeutic strategy. Drug Discov. Today: Ther. Strate. 2005;2:313-321.
23. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-1805.
24. Ye G, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr Opin Investig Drugs 2008;9:605-613.
25. Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999;7:651-661.
26. Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 2002;8:2430-2436.
27. Meyn MA 3rd, Smithgall TE. Small molecule inhibitors of Lck: The search for specificity within a kinase family. Mini Rev Med Chem 2008;8:628-637.
28. Schenone S, Brullo C, Musumeci F, Biava M, Falchi F, Botta M. Fyn kinase in brain diseases and cancer: The search for inhibitors. Curr Med Chem 2011;18:2921-2942.
29. Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003;39:1927-1935.
30. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512.
31. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002;21:8075-8088.
32. Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 2008;27:7055-7069.
33. Gangjee A, Vidwans A, Elzein E, McGuire JJ, Queener SF, Kisliuk RL. Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d] pyrimidines. J Med Chem 2001;44:1993-2003.
34. Technical Bulletin. ProFluor Src-family kinase assay, Revised 6/09, Promega Corporation, USA